Global pharmaceutical filtration market value of USD 20,190.1 million by 2020
Analysis, trends and opportunities report 2016–2020 — key vendors: General Electric, Pall Corporation, 3M.
Research and Markets has added "Pharmaceutical Filtration Market by Product (Membrane Filters, Single-use systems), Techniques (Ultrafiltration, Cross Flow Filtration), Applications, Scale of Operations, Geography (North America, Europe) — Global Forecast to 2020" report to their offering.
This comprehensive report predicts that the global market will be worth USD 20,190.1 million by 2020. The major drivers for the market include the growth of biopharmaceutical industry, advancement in nanofiber technology, rapid expansion in generic drug production, increasing incidences of airborne disease, and strong biologics product pipeline. The emerging nations will provide new growth opportunities for this market. The report provides a granular understanding of the market for pharmaceutical filtration. This report segments the global market on the basis of product, technique, application, scale of operation, and geographies. The product segments included in this report are membrane filters, prefilters and depth media, cartridges and capsules, single-use systems, filter holders, filtration accessories.
The major players in this market include Merck & Co., Inc. (US), General Electric Company (US), Pall Corporation (US), Parker Hannifin Corporation (US), Sartorius Stedim Biotech Group (France), and 3M (US), Eaton Corporation Plc (Ireland), Amazon Filters Ltd (United Kingdom), Graver Technologies, LLC. (US), and Meissner Filtration Products, Inc. (US).
Key Topics Covered:Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.